Publications by authors named "Zelin Zhan"
Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials.
Front Endocrinol (Lausanne)
February 2022
Recently, Lin and colleagues assessed the safety of sodium-glucose cotransporter 2 inhibitors (SGLT2is) by a meta-analysis [1], in which the authors assessed 16 kinds of adverse events (AE) reported in the published articles based on 10 randomized controlled trials. We conducted a further meta-analysis and targeted the association between use of SGLT2is and occurrences of various kinds of serious AE published in the Clinical Trials website (clinicaltrials.gov).
View Article and Find Full Text PDFArticle Synopsis
- A meta-analysis was conducted to assess the impact of sodium-glucose transporter 2 inhibitors, specifically gliflozins, on the risk of stroke in type 2 diabetes patients, analyzing multiple recent cardiovascular trials.
- The results showed that gliflozins significantly reduced stroke and major adverse cardiovascular events (MACE) in T2D patients with chronic kidney disease, but did not have a significant effect in those without kidney disease.
- Specific gliflozins, like sotagliflozin, lowered stroke risk, while others had varied effects on MACE but generally showed beneficial outcomes compared to placebo.
Background: The effects of sodium-glucose transporter 2 (SGLT2) inhibitors on cardiovascular death (CV death) and all-cause death (AC death) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are currently under intensive investigation. We intended to conduct an updated meta-analysis including the SCORED trial to evaluate the effects of SGLT2 inhibitors on death and cardiorenal events in this vulnerable population.
Methods: Cardiorenal outcome trials of SGLT2 inhibitors were included.
The cardiorenal benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) are established, whereas those in patients without T2DM are not established. We sought to assess the cardiorenal efficacy and safety of SGLT2 inhibitors in non-T2DM patients by performing a meta-analysis based on the subgroup data of non-T2DM patients from relevant secondary analysis articles in which subgroup analyses were done according to the status of diabetes. Compared to placebo, SGLT2 inhibitors significantly reduced heart failure hospitalization [risk ratio (RR) 0.
View Article and Find Full Text PDFBackground: The impact of time factor and patient characteristics on the efficacy of percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary-artery bypass grafting (CABG) for left main coronary disease is unclear.
Methods: We searched PubMed and Embase for related trials.
Purpose: The impact of use of sodium-glucose transporter 2 (SGLT2) inhibitors on occurrence of various kinds of respiratory disorders has not been established. We aimed at evaluating the relationship between use of SGLT2 inhibitors and occurrence of 9 kinds of noninfectious respiratory disorders.
Methods: Large randomized controlled trials (RCTs) of SGLT2 inhibitors were included in this study.